The Democratic Republic of Congo (DRC) has launched a clinical trial of a new Ebola vaccine candidate as health authorities intensify efforts to contain an outbreak that has spread beyond its borders.
The TUMAiNi trial began on Saturday in Bunia, the capital of Ituri Province, and will assess candidate vaccines against the Bundibugyo virus among people who have had contact with confirmed Ebola cases.
The initiative comes as the DRC grapples with what has been described in the report as the deadliest and fastest-growing Ebola outbreak in its history, raising concerns about the capacity of affected countries to contain the disease.
The trial is being led by the National Institute for Biomedical Research (INRB), the DRC’s national public health laboratory, with technical, scientific and logistical support from the World Health Organisation (WHO).
Speaking at the launch, Ituri Province Governor, Major General Kasongo Gaby, described the trial as a significant step in the response to the outbreak.
“This event is of particular importance. It reflects our shared determination not to passively accept health threats, but to mobilise all available resources,” he said.
The study is expected to contribute to efforts to evaluate potential vaccine protection against the Bundibugyo strain, one of the Ebola virus species for which developing effective vaccines remains a challenge.
The outbreak has placed increasing pressure on public health authorities, with the disease reported in several African countries.
According to the report, the DRC has confirmed more than 9,000 Ebola cases since the outbreak was declared in mid-May. Kenya has reported nine cases, while Nigeria confirmed its first case this week.
Uganda, which reported 20 cases during the outbreak, was declared Ebola-free in August.
The spread of the disease has heightened the need for coordinated surveillance, rapid identification of contacts and strengthened preparedness across the region.
The TUMAiNi trial represents another effort to expand the scientific response to the outbreak, although its findings will be needed to establish the safety and effectiveness of the vaccine candidates under evaluation.
Health authorities continue to face the challenge of containing transmission while pursuing research that could strengthen protection against the Bundibugyo virus.
 has launched a clinical trial of a new Ebola vaccine candidate as health authorities intensify efforts){kind=link}